Aspirin and lipid mediators in the cardiovascular system

Prostaglandins and Other Lipid Mediators

Volumn 121, Issue , 2015, Pages 17-23

  Schrör, Karsten ^a   Rauch, Bernhard H ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Aspirin; Cycloxygenases; Lipoxins; Nitric oxide; Prostaglandins; Sphingosine 1 phosphate; Thromboxane

Indexed keywords

5 HYDROXYICOSATETRAENOIC ACID; ACETYLSALICYLIC ACID; ANALGESIC AGENT; ASPIRIN TRIGGERED LIPOXIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEME OXYGENASE 1; LIPID; LIPOXIN; LIPOXYGENASE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN; PROTON PUMP INHIBITOR; SPHINGOSINE 1 PHOSPHATE; THROMBOXANE; THROMBOXANE A2; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; HUMAN; INFLAMMATION; LEUKOCYTE; MEDIATOR; META ANALYSIS; OXIDATIVE STRESS; PARACRINE SIGNALING; PHARMACOLOGY; PRIMARY PREVENTION; PROTEIN ACETYLATION; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; RECEPTOR UPREGULATION; SECONDARY PREVENTION; THROMBOCYTE; THROMBOCYTE AGGREGATION; ULCEROGENESIS; DRUG EFFECTS; LIPID METABOLISM; METABOLISM; MOLECULARLY TARGETED THERAPY;

ASPIRIN; CARDIOVASCULAR SYSTEM; HUMANS; LIPID METABOLISM; MOLECULAR TARGETED THERAPY;

EID: 84949723463     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2015.07.004     Document Type: Review

References (67)

1. H. Dreser Pharmakologisches über Aspirin (Acetylsalizylsäure) Pflügers Arch. Physiol. 76 1899 306 318
2. J.R. Vane Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs Nat. New Biol. 231 25 1971 232 235
3. G.J. Roth, N. Stanford, and P.W. Majerus Acetylation of prostaglandin synthase by aspirin Proc. Natl. Acad. Sci. U. S. A. 72 8 1975 3073 3076
4. K.M. Starko Salicylates and pandemic influenza mortality, 1918-1919 pharmacology, pathology, and historic evidence Clin. Infect. Dis. 49 9 2009 1405 1410
5. Jigang Wang, Chong-Jing Zhang, Jianbin Zhang, Yingke He, Yew Mun Lee, Songbi Chen, Teck Kwang Lim, Shukie Ng, Han-Ming Shen, and Qingsong Lin Sci. Rep. 5 2015 7896 10.1038/srep07896
6. L. Alfonso, and et al. Molecular targets of aspirin and cancer prevention Br. J. Cancer 111 1 2014 61 67
7. 4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation J. Exp. Med. 200 1 2004 69 78
8. V. Nascimento-Silva, and et al. Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells Am. J. Physiol. Cell Physiol. 289 3 2005 C557 C563
9. J.S. Paikin, and J.W. Eikelboom Cardiology patient page: aspirin Circulation,. 125 10 2012 439 442
10. G. Montalescot, and et al. ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology Eur. Heart J. 34 38 2013 2949 3003
11. Ruffin, M.T. t, and et al. Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose J. Natl. Cancer Inst. 89 15 1997 1152 1160
12. J. Nagelschmitz, M. Blunk, J. Krätschmar, and et al. Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers Clin. Pharmacol.: Adv. Appl. 5 2013 1 9
13. Acetylsalicylic Acid K. Schrör 1st ed. 2009 Wiley VCH Weinheim 376
14. B. Frantz, and E.A. O'Neill The effect of sodium salicylate and aspirin on NF-kappa B Science 270 5244 1995 2017 2019
15. M. Lee, B. Cryer, and M. Feldman Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury Ann. Intern. Med. 120 3 1994 184 189
16. J. Nagelschmitz, M. Blunk, J. Krätschmar, and et al. Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers Clin. Pharmacol. Adv. Appl. 5 2013 1 9
17. T.D. Warner, and et al. Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2 FASEB J. 20 3 2006 542 544
18. C.H. Hennekens, and et al. Terms and conditions: semantic complexity and aspirin resistance Circulation 110 12 2004 1706 1708
19. K. Schrör, and K.T. Huber Hohlfeld Functional testing methods for the antiplatelet effects of aspirin Biomark. Med. 5 1 2011 31 42
20. E.G. Kovacs, and et al. New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; the lack of aspirin resistance among healthy individuals Thromb. Res. 131 4 2013 320 324
21. P. Patrignani, and P.C. Filabozzi Patrono Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects J. Clin. Invest. 69 6 1982 1366 1372
22. T. Hohlfeld, A. Saxena, and K. Schror High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs-pharmacological mechanisms and clinical relevance Thromb. Haemost. 109 5 2013 825 833
23. A. Polzin, and et al. Dipyrone (metamizole) can nullify the antiplatelet effect of aspirin in patients with coronary artery disease J. Am. Coll. Cardiol. 2013 1725 1726
24. P. Henry, and et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease Thromb. Haemost. 105 2 2010 336 344
25. J.G. Dillinger, and et al. Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease Am. Heart J. 164 4 2012 600 606 e1
26. G.A. FitzGerald, and et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man J. Clin. Invest. 71 3 1983 676 688
27. R.L. Czervionke, and et al. Inhibition of prostacyclin by treatment of endothelium with aspirin. Correlation with platelet adherence J. Clin. Invest. 63 5 1979 1089 1092
28. J.M. Gerrard, and et al. In vivo measurement of thromboxane B2 and 6-keto-prostaglandin F1 alpha in humans in response to a standardized vascular injury and the influence of aspirin Circulation 79 1 1989 29 38
29. B.F. McAdam, and et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2 Proc. Natl. Acad. Sci. U. S. A. 96 1 1999 272 277
30. N.S. Kirkby, and et al. Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system Proc. Natl. Acad. Sci. U. S. A. 109 43 2012 17597 17602
31. E. Ricciotti, and et al. COX-2, the dominant source of prostacyclin Proc. Natl. Acad. Sci. U. S. A. 110 3 2013 E183
32. Y. Yu, and et al. Vascular COX-2 modulates blood pressure and thrombosis in mice Sci. Transl. Med. 4 132 2012 p. 132ra54
33. O. Belton, and et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis Circulation 102 8 2000 840 845
34. A.S. Weyrich, S. Lindemann, and G.A. Zimmerman The evolving role of platelets in inflammation J. Thromb. Haemost. 1 9 2003 1897 1905
35. P.M. Ridker, and et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men N. Engl. J. Med. 336 14 1997 973 979
36. J.B. Muhlestein Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients Thromb. Haemost. 103 1 2010 71 82
37. G. Passacquale, and A. Ferro Current concepts of platelet activation: possibilities for therapeutic modulation of heterotypic vs. homotypic aggregation Br. J. Clin. Pharmacol. 72 4 2011 604 618
38. J. Liang, and et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer Cancer Cell 23 1 2013 107 120
39. S. Spiegel, and S. Milstien The outs and the ins of sphingosine-1-phosphate in immunity Nat. Rev. Immunol. 11 6 2011 403 415
40. T. Ulrych, and et al. Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation J. Thromb. Haemost. 9 4 2011 790 798
41. S. Mahajan-Thakur, and et al. Sphingosine-1-phosphate induces thrombin receptor PAR-4 expression to enhance cell migration and COX-2 formation in human monocytes J. Leukocyte Biol. 96 4 2014 611 618
42. A. Polzin, and et al. Aspirin inhibits release of platelet-derived sphingosine-1-phosphate in acute myocardial infarction Int. J. Cardiol. 170 2 2013 e23 e24
43. C.N. Serhan Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways Annu. Rev. Immunol. 25 2007 101 137
44. M. Spite, and C.N. Serhan Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins Circ. Res. 107 10 2010 1170 1184
45. J.A. Mancini, and et al. Mutation of serine-516 in human prostaglandin G/H synthase-2 to methionine or aspirin acetylation of this residue stimulates 15-R-HETE synthesis FEBS Lett. 342 1 1994 33 37
46. M. Lecomte, and et al. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin J. Biol. Chem. 269 18 1994 13207 13215
47. J. Claria, and C.N. Serhan Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions Proc. Natl. Acad. Sci. U. S. A. 92 21 1995 9475 9479
48. E.A. Meade, W.L. Smith, and D.L. DeWitt Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs J. Biol. Chem. 268 9 1993 6610 6614
49. J.A. Mancini, and et al. Altered sensitivity of aspirin-acetylated prostaglandin G/H synthase-2 to inhibition by nonsteroidal anti-inflammatory drugs Mol. Pharmacol. 51 1 1997 52 60
50. T. Morris, and et al. Effects of low-dose aspirin on acute inflammatory responses in humans J. Immunol. 183 3 2009 2089 2096
51. D. Taubert, and et al. Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action Br. J. Pharmacol. 143 1 2004 159 165
52. S.B. Jung, and et al. Histone deacetylase 3 antagonizes aspirin-stimulated endothelial nitric oxide production by reversing aspirin-induced lysine acetylation of endothelial nitric oxide synthase Circ. Res. 107 7 2010
53. N. Grosser, and et al. Heme oxygenase-1 induction may explain the antioxidant profile of aspirin Biochem. Biophys. Res. Commun. 308 4 2003 956 960
54. N. Grosser, and H. Schröder Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway Arterioscler Thromb. Vasc. Biol. 23 8 2003 1345 1351
55. S. Husain, and et al. Aspirin improves endothelial dysfunction in atherosclerosis Circulation 97 8 1998 716 720
56. J.P. Noon, and et al. Impairment of forearm vasodilatation to acetylcholine in hypercholesterolemia is reversed by aspirin Cardiovasc. Res. 38 2 1998 480 484
57. C.H. Hennekens, and et al. A randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans J. Cardiovasc. Pharmacol. Ther. 15 4 2010 344 348
58. S. Hetzel, and et al. Aspirin increases nitric oxide formation in chronic stable coronary disease J. Cardiovasc. Pharmacol. Ther. 18 3 2013
59. P.M. Rothwell, and et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials Lancet 379 9826 2012 1602 1612
60. L. Cea Soriano, and et al. Cardiovascular and upper gastrointestinal bleeding consequences of low-dose acetylsalicylic acid discontinuation Thromb. Haemost. 110 6 2013 1298 1304
61. D.L. Bhatt, and et al. ACCF/ACG/AHAexpert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use Am. J. Gastroenterol. 103 11 2008 2890 2907
62. J. Cuzick, and et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population Ann. Oncol. 26 1 2014 47 57
63. J. Simes, and et al. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration Circulation 130 13 2014 1062 1071
64. D.R. Anderson, and et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial Ann. Intern. Med. 158 11 2013 800 806
65. M.L. LeFevre Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U. S. preventive services task force recommendation statement Ann. Intern. Med. 161 11 2014 819 826
66. A.T. Chan, and et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview Cancer Prev. Res. (Phila) 5 2 2011 164 178
67. H. Li, K. Liu, L.A. Boardman, and et al. Circulating prostaglandin biosynthesis in colorectal cancer and potential clinical significance EBioMedicine 2014